ArticleMedical oncology (Northwood, London, England)2013

Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.

Linda Sooman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.